The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
A systematic review of the cost and cost‐effectiveness studies of proton radiotherapy
Abstract
BACKGROUND: Economic analyses of new technologies, such as proton‐beam radiotherapy (PBT), are a public health priority. To date, no systematic review of the cost‐effectiveness of PBT has been performed. METHODS: Systematic searches of PubMed, EMBASE, abstracts from American Society for Radiation Oncology and American Society of Clinical Oncology meetings, and the Cost‐Effectiveness Analysis Registry were conducted (2000‐2015) along with abstracts from the Particle Therapy Co‐Operative Group of North America for both years of existence (2014‐2015). Eighteen original investigations were analyzed. RESULTS: The cost‐effectiveness for prostate cancer—the single most common diagnosis currently treated with PBT—was suboptimal. PBT was the most cost‐effective option for several pediatric brain tumors. PBT costs for breast cancer were increased but were favorable for appropriately selected patients with left‐sided cancers at high risk of cardiac toxicity and compared with brachytherapy for accelerated partial breast irradiation. For non‐small cell lung cancer (NSCLC), the greatest cost‐effectiveness benefits using PBT were observed for locoregionally advanced—but not early stage—tumors. PBT offered superior cost‐effectiveness in selected head/neck cancer patients at higher risk of acute mucosal toxicities. Similar cost‐effectiveness was observed for PBT, enucleation, and plaque brachytherapy in patients with uveal melanoma. CONCLUSIONS: With greatly limited amounts of data, PBT offers promising cost‐effectiveness for pediatric brain tumors, well‐selected breast cancers, locoregionally advanced NSCLC, and high‐risk head/neck cancers. Heretofore, it has not been demonstrated that PBT is cost‐effective for prostate cancer or early stage NSCLC. Careful patient selection is absolutely critical to assess cost‐effectiveness. Together with increasing PBT availability, clinical trial evidence, and ongoing major technological improvements, cost‐effectiveness data and conclusions from this analysis could change rapidly. Cancer 2016;122:1483–501. © 2016 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2010) · International Journal of Surgery · doi:10.1016/j.ijsu.2010.02.007 · Cited by 12,156
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209825 · Cited by 3,974
Recommendations of the Panel on Cost-Effectiveness in Health and Medicine
Weinstein, M. C. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540150055031 · Cited by 2,455 · cited 1×
“It has been postulated by the Panel for CostEffectiveness in Health and Medicine that these conditions as well as others are necessary for high-quality and reliable CE analyses.(60) Other discussion points set forth include the necessary inclusion of quality-of-life data (of which there are very little for PBT to date…”
BackgroundUpdating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold
Neumann, P. J., Cohen, J. T., & Weinstein, M. C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1405158 · Cited by 2,249
Cited by
Nasopharyngeal carcinoma: an evolving paradigm
Wong, K. C. W., Hui, E. P., Lo, K.-W., Lam, W. K. J., Johnson, D., Li, L., Tao, Q., Chan, K. C. A., To, K.-F., King, A. D., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00524-x · Cited by 546
Contemporary radiotherapy: present and future
Chandra, R. A., Keane, F. K., Voncken, F. E. M., & Thomas, C. R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00233-6 · Cited by 380
A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
Verma, V., Sprave, T., Haque, W., Simone, C. B., Chang, J. Y., Welsh, J. W., & Thomas, C. R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0442-7 · Cited by 319
Self-citationPeeler, C. R., Mirkovic, D., Titt, U., Blanchard, P., Gunther, J. R., Mahajan, A., Mohan, R., & Grosshans, D. R. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.11.001 · Cited by 271
Metadata
- Authors
- Verma, V., Mishra, M. V., & Mehta, M. P.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2016-02
- Volume
- 122
- Issue
- 10
- Pages
- 1483-1501
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2271996082
- Cited by
- 242
- References
- 4
- FWCI
- 6.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A systematic review of the cost and cost‐effectiveness studies of proton radiotherapy. https://app.cochat.ai/papers/10.1002/cncr.29882
- The paper
- Verma, V., Mishra, M. V., & Mehta, M. P. (2016). A systematic review of the cost and cost‐effectiveness studies of proton radiotherapy. Cancer. https://doi.org/10.1002/cncr.29882
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.